Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTHEM, INC.

(ANTM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ANTHEM, INC. : Regulation FD Disclosure (form 8-K)

09/08/2021 | 04:33pm EDT

Item 7.01 Regulation FD Disclosure.

Officers of Anthem, Inc. (the "Company") will speak with investors over the next several weeks. During these meetings, Company officers intend to reaffirm the Company's net income guidance for full year 2021 to be greater than $24.89 per share, including approximately $0.61 per share of net unfavorable items. Excluding these items, the Company continues to expect adjusted net income to be greater than $25.50 per share. This guidance does not include any other adjustment items beyond those reported in the Company's second quarter 2021 earnings release.

None of the information furnished in Item 7.01 hereto shall be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

FORWARD-LOOKING STATEMENTS

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as "expect," "feel," "believe," "will," "may," "should," "anticipate," "intend," "estimate," "project," "forecast," "plan" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates; the impact of federal and state regulation, including ongoing changes in the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; reduced enrollment; unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; risks and uncertainties related to our pharmacy benefit management ("PBM"), business including non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.; medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; changes in U.S. tax laws; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; the impact of international laws and regulations; intense competition to attract and retain employees; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ANTHEM, INC.
04:50pUS Stocks Gain for Sixth Day; Dow Sets Intraday Record as Verizon Earnings Impress
MT
04:47pCLOSE UPDATE : US Stocks Gain for Sixth Day; Dow Sets Intraday Record as Verizon Earnings ..
MT
04:21pBrinker, Baker Hughes fall; Anthem, Abbott Laboratories rise
AQ
03:52pHealth Care Stocks Rally for Second Consecutive Day
MT
01:29pEquities Advance Midday While Treasury Yields Remain Close to Highest Level Since May
MT
01:25pHealth Care Stocks Rally Second Consecutive Day
MT
01:18pMIDDAY REPORT : US Stocks Advance While Treasury Yields Remain Close to Highest Level Sinc..
MT
12:17pANTHEM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERAT..
AQ
11:53aHealth insurer Anthem signals smaller pandemic hit next year
RE
11:51aANTHEM : Raises 2021 Guidance Following Third-Quarter Beat on Strong Segment Growth Despit..
MT
More news
Analyst Recommendations on ANTHEM, INC.
More recommendations
Financials (USD)
Sales 2021 138 B - -
Net income 2021 6 126 M - -
Net Debt 2021 17 741 M - -
P/E ratio 2021 15,9x
Yield 2021 1,09%
Capitalization 103 B 103 B -
EV / Sales 2021 0,88x
EV / Sales 2022 0,79x
Nbr of Employees 83 400
Free-Float 99,3%
Chart ANTHEM, INC.
Duration : Period :
Anthem, Inc. Technical Analysis Chart | ANTM | US0367521038 | MarketScreener
Technical analysis trends ANTHEM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 393,75 $
Average target price 433,52 $
Spread / Average Target 10,1%
EPS Revisions
Managers and Directors
Gail Koziara Boudreaux President, Chief Executive Officer & Director
John Edward Gallina Chief Financial Officer & Executive Vice President
Elizabeth E. Tallett Independent Chairman
Gloria M. McCarthy Chief Administrative Officer & Executive VP
Ramiro G. Peru Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANTHEM, INC.20.90%96 002
UNITEDHEALTH GROUP21.08%400 155
CIGNA CORPORATION-1.73%70 276
HUMANA INC.6.89%56 735
CENTENE CORPORATION7.80%37 729
MOLINA HEALTHCARE, INC.32.56%16 464